Considering that the device can be adapted to treat other mental illnesses such as depression/anxiety, bipolar disorder and schizophrenia which represent a vastly greater proportion of the public than those who are autistic, we could be looking at a multi billion market cap in the future if it's not taken over by a bigger company by then.
